SABCS: Breast Cancer Survival Up With Everolimus + Exemestane

Share this content:
SABCS: Breast Cancer Survival Up With Everolimus + Exemestane
SABCS: Breast Cancer Survival Up With Everolimus + Exemestane

(HealthDay News) - Everolimus plus exemestane improves progression-free survival (PFS) for postmenopausal women with hormone-receptor (HR)-positive breast cancer; and pertuzumab plus trastuzumab plus docetaxel improves PFS in human epidermal growth factor receptor type 2 (HER2)-positive metastatic breast cancer, according to two studies published online December 7, 2011 in the New England Journal of Medicine to coincide with presentation at the annual San Antonio Breast Cancer Symposium, held from December 6 to 10.

José Baselga, MD, PhD (of the Massachusetts General Hospital Cancer Center in Boston) and colleagues compared the safety and efficacy of everolimus and exemestane with that of placebo and exemestane in 724 postmenopausal women with HR-positive breast cancer, who had recurrence or progression during treatment with nonsteroidal aromatase inhibitors, advanced disease, or both. PFS was the primary end point. The local investigators found that the everolimus plus exemestane and placebo groups had median PFS of 6.9 and 2.8 months, respectively (HR, 0.43), while according to central assessment, median PFS was 10.6 and 4.1 months, respectively (HR, 0.36).

In another study, Baselga and colleagues compared the safety and efficacy of pertuzumab plus trastuzumab and docetaxel (pertuzumab group) with that of placebo plus trastuzumab and docetaxel (control group), as first-line treatment for 808 patients with HER2-positive metastatic breast cancer. PFS was the primary end point. The median PFS was 12.4 and 18.5 months in the control and pertuzumab groups, respectively (HR, 0.62).

"The combination of the anti-HER2 monoclonal antibodies pertuzumab and trastuzumab with docetaxel as first-line therapy prolonged progression-free survival in patients with HER2-positive metastatic breast cancer," write the authors of the second study.

The first study was funded by Novartis; the second study was funded by F. Hoffmann-La Roche and Genentech. Authors from both studies disclosed financial relationships with pharmaceutical companies, including those funding the studies.

Abstract 1
Full Text
Abstract 2
Full Text
Editorial
More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs